Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | TGM2 | P21980 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648611 | 0.75 | NPC1 (0.54) | NPC1RAB9AKMT2A | |
| SCHEMBL2955543 | 0.75 | CDK4 (0.42) | GSK3AGSK3BMAPK1NPC1RAB9A | |
| SCHEMBL2779688 | 0.74 | MAPK14 (0.43) | MAPK14GSK3AGSK3BGAAKMT2A | |
| SCHEMBL5649021 | 0.70 | KMT2A (0.39) | MAPK14GSK3AGSK3BTGM2MAPK1 | |
| SCHEMBL5654089 | 0.70 | KMT2A (0.38) | MAPK14GSK3AGSK3BMAPK1NPC1 | |
| SCHEMBL5650705 | 0.68 | KMT2A (0.43) | GSK3AGSK3BMAPK1RAB9AKMT2A | |
| SCHEMBL1267071 | 0.67 | ALDH1A1 (0.43) | MAPK14MAPK1NPC1RAB9AGAA | |
| SCHEMBL2948995 | 0.67 | FADS1 (0.42) | GSK3BNPC1RAB9AGAAKMT2A | |
| SCHEMBL5650413 | 0.67 | ALDH1A1 (0.42) | MAPK14GSK3AGSK3BMAPK1GAA | |
| SCHEMBL5651010 | 0.66 | KMT2A (0.35) | MAPK14GSK3AGSK3BMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | claimed |
| US-20050059681-A1 | Far field light microscopical method system and computer program product for analysing at least one object having a subwavelength size | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2005-03-17 | — | — | US | claimed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | claimed |
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059681-A1 | Far field light microscopical method system and computer program product for analysing at least one object having a subwavelength size | CFL1, INF2, COG6 | MAPK14 4195/4885GRM1 1403/4885GSK3A 4879/4885 |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | MAPK14 31/4885GRM1 689/4885GSK3A 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.